# US 2021/0079008 A1 · Benzimidazoles and Methods of Using Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079008 A1
- Document ID: US20210079008A1
- Status: Published application
- Kind: A1
- Application number: 17/023,323
- Filed: 2020-09-16
- Published: 2021-03-18
- Earliest claimed: 2019-09-17
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Darrell Davis; Shuanghu Liu
- Web page: https://patentgrep.com/patent/US20210079008A1

## CPC

- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 491/147: the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- A61K 31/381: having five-membered rings
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 495/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is concerned with benzimidazole compounds and methods of using these compounds for the treatment of hepatitis (e.g., hepatitis C), RNA virus infections (e.g., Zika virus, dengue virus, Powassan virus, Chikungunya virus, Enterovirus, respiratory syntactical virus (RSV), Rift Valley fever, Influenza virus, Tacaribe virus, Mayaro virus, West Nile virus, yellow fever virus, and coronavirus), and disorders of uncontrolled cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A compound having a structure represented by a formula selected from:
wherein is a single or a double covalent bond;
wherein n is 0 or 1;
wherein Z, when present, is selected from N and CR10;
wherein R10, when present, is selected from hydrogen and halogen;
wherein R1 is selected from —(C1-C4 alkyl)OR11, —(C1-C4 alkyl)NR12aR12b, —CO2R13, and —C(O)NR14aR14b;
wherein each of R11, R12a, and R12b, when present, is independently selected from hydrogen, C1-C4 alkyl, —C(═NH)NH2, —CO2(C1-C4 alkyl), —(C1-C4 alkyl)OR20, —(C1-C4 alkyl)NR21aR21b, —(C1-C4 alkyl)Ar1, and Ar1;
wherein Ar1, when present, is selected from aryl and heteroaryl and substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein each of R13, R14a, and R14b, when present, is independently selected from hydrogen and C1-C4 alkyl;
wherein R2, when present, is selected from C1-C4 alkyl and —(C1-C4 alkyl)NR15aR15b;
wherein each of R15a and R15b, when present, is independently selected from hydrogen and C1-C4 alkyl;
wherein R3 is selected from hydrogen and C1-C4 alkyl;
or wherein each of R2, when present, and R3 together comprise a 5- to 6-membered heterocycle substituted with a group selected from C1-C4 alkyl and —(C1-C4 alkyl)NR16aR16b;
wherein each of R16a and R16b, when present, is independently selected from hydrogen and C1-C4 alkyl; and
wherein Ar2 is a heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
provided that when the compound has a structure represented by a formula:
then either is a double bond, Z is CR10, or R2 is C1-C4 alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein is a double covalent bond.

### Claim 3 (depends on 1)

The compound of claim 1, n is 0.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Z is CR10.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is selected from —(C1-C4 alkyl)NR12aR12b and —C(O)NR14aR14b.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is —(C1-C4 alkyl)NR12aR12b.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is —CH2NR12aR12b.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R1 is —CH2NMe2.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is selected from —CO2R13 and —C(O)NR14aR14b.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R1 is selected from —CO2Me and —C(O)NMe2.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is —(C1-C4 alkyl)NR15aR15b.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R2 is —(C1-C4 alkyl)NMe2.

### Claim 13 (depends on 1)

The compound of claim 1, wherein Ar2 is 5-membered heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is selected from:

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is selected from:

### Claim 16 (depends on 1)

A method for treating hepatitis in a subject, the method comprising administering to the subject an effective amount of the compound of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein hepatitis is hepatitis C.

### Claim 18

A method for treating a RNA virus infection in a subject, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula selected from:
wherein is a single or a double covalent bond;
wherein n is 0 or 1;
wherein Z, when present, is selected from N and CR10;
wherein R10, when present, is selected from hydrogen and halogen;
wherein R1 is selected from —(C1-C4 alkyl)OR11, —(C1-C4 alkyl)NR12aR12b, —CO2R13, and —C(O)NR14aR14b;
wherein each of R11, R12a, and R12b, when present, is independently selected from hydrogen, C1-C4 alkyl, —C(═NH)NH2, —CO2(C1-C4 alkyl), —(C1-C4 alkyl)OR20, —(C1-C4 alkyl)NR21aR21b, —(C1-C4 alkyl)Ar1, and Ar1;
wherein Ar1, when present, is selected from aryl and heteroaryl and substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein each of R13, R14a, and R14b, when present, is independently selected from hydrogen and C1-C4 alkyl;
wherein R2, when present, is selected from C1-C4 alkyl and —(C1-C4 alkyl)NR15aR15b;
wherein each of R15a and R15b, when present, is independently selected from hydrogen and C1-C4 alkyl;
wherein R3 is selected from hydrogen and C1-C4 alkyl;
or wherein each of R2, when present, and R3 together comprise a 5- to 6-membered heterocycle substituted with a group selected from C1-C4 alkyl and —(C1-C4 alkyl)NR16aR16b;
wherein each of R16a and R16b, when present, is independently selected from hydrogen and C1-C4 alkyl;
wherein each of R4 and R5 is hydrogen or together comprise a 5- to 6-membered heterocycle; and
wherein Ar2 is a heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
provided that when each of R4 and R5 is hydrogen, then R is —(C1-C4 alkyl)OR11 or —(C1-C4 alkyl)NR12aR12b,
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the RNA virus is selected from Zika virus, dengue virus, Powassan virus, Chikungunya virus, Enterovirus, respiratory syntactical virus (RSV), Rift Valley fever, Influenza virus, Tacaribe virus, Mayaro virus, West Nile virus, yellow fever virus, and coronavirus.

### Claim 20 (depends on 19)

The method of claim 19, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
